Three phase 1/2, open-label studies of cereblon e3 ligase modulator (celmod)-based regimens in newly diagnosed (nd) or relapsed/refractory (r/r) non-hodgkin lymphoma (nhl)
Hematological Oncology(2021)
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要